Diagnostic algorithm and therapeutic options in chronic heart failure: Updated review of clinical practice guidelines

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 9, 2008, Pages 489-500

  Gajos, Grzegorz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Chronic heart failure; Diagnostic techniques; Practice guidelines; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE;

ALGORITHM; CLINICAL PRACTICE; DEFIBRILLATOR; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 53049098741     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.466     Document Type: Review

References (21)

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005; 26: 1115-1140.
2. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 2005;46:e1-e82. Erratum in: J Am Coll Cardiol. 2006; 47: 1 503-1 505.
3. Heart Failure Society Of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006; 12: 10-38.
4. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006; 22: 2345.
5. Lenzen MJ, Boersma E, Reimer WS, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005; 26: 2706-2713.
6. Pitt B, Zannad F, Remme W, et al. The Randomized Aldactone Evaluation Study Investigators, The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med 1999 341: 709-717.
7. Cohn JN, Jay N, Tognoni G, Gianni; the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345: 1667-1675
8. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362(9386):767-771.
9. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. Int J Cardiol. 2008; 123: 138-146.
10. McMurray JJ, Swedberg K. Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J. 2006; 27: 1773-1777.
11. Ahmed A, Young JB, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.. Eur Heart J. 2006; 27: 1431-1439.
12. GESICA Investigators. Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ. 2005; 331: 425.
13. Ezekowitz JA, van Walraven C, McAlister FA, et al. Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ. 2005; 172: 189-194.
14. Wierzchowiecki M, Poprawski K, Nowicka A, et al. A new programme of multidisciplinary care for patients with heart failure in Poznań: one-year follow-up. Kardiol Pol. 2006; 64: 1063-1070.
15. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP multicenter study. J Am Coll Cardiol 2007; 49: 1733-1739.
16. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J. 2004; 25: 1788-1796.
17. Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Eur Heart J. 2007; 28: 2256-2295.
18. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J. 2006; 27: 2682-2688.
19. Cleland JG, Abdellah AT, Khaleva, O et al. Clinical trials update from the European Society of Cardiology Congress 2007: 3CP0, ALOFT, PROSPECT and statins for heart failure. Eur J Heart Fail. 2007; 9: 1070-1073.
20. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2006; 8: 746-837.
21. Smith S, Allen J, Blair S, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol. 2006; 47: 2130-2139.